These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

384 related articles for article (PubMed ID: 12957454)

  • 1. Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study.
    Verweij J; van Oosterom A; Blay JY; Judson I; Rodenhuis S; van der Graaf W; Radford J; Le Cesne A; Hogendoorn PC; di Paola ED; Brown M; Nielsen OS
    Eur J Cancer; 2003 Sep; 39(14):2006-11. PubMed ID: 12957454
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Imatinib mesylate in the treatment of advanced gastrointestinal stromal tumors].
    Wan DS; Wu XJ; Pan ZZ; Zhou ZW; Chen G; Li LR; Lu ZH; Ding PR
    Zhonghua Yi Xue Za Zhi; 2006 Nov; 86(43):3064-7. PubMed ID: 17288838
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A pilot study of imatinib mesylate (STI571) on gastrointestinal stromal tumors in Japanese patients.
    Sawaki A; Yamao K; Nakamura T; Suzuki T; Okubo K; Hara K; Kawai H; Yamamura Y; Ito S; Mochiduki Y; Ohno R
    J Gastroenterol; 2004; 39(4):329-33. PubMed ID: 15168243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Imatinib mesylate alone for refractory advanced gastrointestinal stromal tumor].
    Shen L; Jin ML
    Zhonghua Zhong Liu Za Zhi; 2004 Nov; 26(11):697-9. PubMed ID: 15777512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brostallicin, an agent with potential activity in metastatic soft tissue sarcoma: a phase II study from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
    Leahy M; Ray-Coquard I; Verweij J; Le Cesne A; Duffaud F; Hogendoorn PC; Fowst C; de Balincourt C; di Paola ED; van Glabbeke M; Judson I; Blay JY;
    Eur J Cancer; 2007 Jan; 43(2):308-15. PubMed ID: 17095209
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.
    Demetri GD; von Mehren M; Blanke CD; Van den Abbeele AD; Eisenberg B; Roberts PJ; Heinrich MC; Tuveson DA; Singer S; Janicek M; Fletcher JA; Silverman SG; Silberman SL; Capdeville R; Kiese B; Peng B; Dimitrijevic S; Druker BJ; Corless C; Fletcher CD; Joensuu H
    N Engl J Med; 2002 Aug; 347(7):472-80. PubMed ID: 12181401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Imatinib in gastrointestinal stromal tumor treatment--results from University Hospital Centre Zagreb].
    Vrbanec D; Petricević B; Majerović M; Stern-Padovan R; Belev B; Skegro M; Herceg D; Plestina S; Dedić-Plavetić N; Jakić-Razumović J
    Lijec Vjesn; 2006; 128(5-6):161-6. PubMed ID: 16910417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study.
    Hotte SJ; Winquist EW; Lamont E; MacKenzie M; Vokes E; Chen EX; Brown S; Pond GR; Murgo A; Siu LL
    J Clin Oncol; 2005 Jan; 23(3):585-90. PubMed ID: 15659505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A prospective, multicenter, phase 2 study of imatinib mesylate in korean patients with metastatic or unresectable gastrointestinal stromal tumor.
    Ryu MH; Kang WK; Bang YJ; Lee KH; Shin DB; Ryoo BY; Roh JK; Kang JH; Lee H; Kim TW; Chang HM; Park JO; Park YS; Kim TY; Kim MK; Lee WK; Kang HJ; Kang YK
    Oncology; 2009; 76(5):326-32. PubMed ID: 19307738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment of patients with gastrointestinal stromal tumour with imatinib mesylate].
    Haugland HK; Jebsen NL; Mannelqvist M; Skar R; Eide J; Øvrebø K; Horn A; Jensen DK; Monge OR; Lilleng PK
    Tidsskr Nor Laegeforen; 2005 Apr; 125(7):868-72. PubMed ID: 15815732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of imatinib mesylate in gastrointestinal stromal tumours: Pan-Birmingham Cancer Network experience.
    Wong DW; Lupton SC; Bhatt L; Gross L; Tanière P; Peake DR; Spooner D; Geh JI
    Clin Oncol (R Coll Radiol); 2008 Sep; 20(7):517-22. PubMed ID: 18514495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML.
    Walker AR; Komrokji RS; Ifthikharuddin J; Messina P; Mulford D; Becker M; Friedberg J; Oliva J; Phillips G; Liesveld JL; Abboud C
    Leuk Res; 2008 Dec; 32(12):1830-6. PubMed ID: 18571721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of imatinib mesylate (Gleevec/Glivec) in gastrointestinal stromal tumors.
    de Jong FA; Verweij J
    Expert Rev Anticancer Ther; 2003 Dec; 3(6):757-66. PubMed ID: 14686698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation of immunophenotype with progression-free survival in patients with gastrointestinal stromal tumors treated with imatinib mesylate.
    Chirieac LR; Trent JC; Steinert DM; Choi H; Yang Y; Zhang J; Patel SR; Benjamin RS; Raymond AK
    Cancer; 2006 Nov; 107(9):2237-44. PubMed ID: 16998931
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors.
    Cohen MH; Farrell A; Justice R; Pazdur R
    Oncologist; 2009 Feb; 14(2):174-80. PubMed ID: 19193781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imatinib mesylate therapy in advanced gastrointestinal stromal tumors: experience from a single institute.
    Hsiao HH; Liu YC; Tsai HJ; Chen LT; Lee CP; Chuan CH; Wang JY; Yang SF; Tseng YT; Lin SF
    Kaohsiung J Med Sci; 2006 Dec; 22(12):599-603. PubMed ID: 17116620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of intratumoral vascular endothelial growth factor expression and clinical outcome for patients with gastrointestinal stromal tumors treated with imatinib mesylate.
    McAuliffe JC; Lazar AJ; Yang D; Steinert DM; Qiao W; Thall PF; Raymond AK; Benjamin RS; Trent JC
    Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6727-34. PubMed ID: 18006774
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.
    Blanke CD; Rankin C; Demetri GD; Ryan CW; von Mehren M; Benjamin RS; Raymond AK; Bramwell VH; Baker LH; Maki RG; Tanaka M; Hecht JR; Heinrich MC; Fletcher CD; Crowley JJ; Borden EC
    J Clin Oncol; 2008 Feb; 26(4):626-32. PubMed ID: 18235122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors.
    Dagher R; Cohen M; Williams G; Rothmann M; Gobburu J; Robbie G; Rahman A; Chen G; Staten A; Griebel D; Pazdur R
    Clin Cancer Res; 2002 Oct; 8(10):3034-8. PubMed ID: 12374669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer.
    Modi S; Seidman AD; Dickler M; Moasser M; D'Andrea G; Moynahan ME; Menell J; Panageas KS; Tan LK; Norton L; Hudis CA
    Breast Cancer Res Treat; 2005 Mar; 90(2):157-63. PubMed ID: 15803362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.